BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR SYSTEMIC TREATMENT OF HEPATOCELLULAR CARCINOMA.
Aline Lopes ChagasCassia Regina Guedes LealVivianne Barretto de MelloFábio Marinho Do Rego BarrosPaulo Bittencourt de MirandaAngelo Alves de MattosDayse C B L ArouchaLeonardo Gomes da FonsecaJoyce Roma Lucas de SilvaMariana Fonseca DottoriRosangela TeixeiraLiliana Sampaio Costa MendesRosamar Eulira Fontes RezendeNorma Arteiro FilgueiraAnelisa K CoutinhoJoão Marcello de Araújo NetoHenrique Sergio Moraes CoelhoMário Guimarães PessoaHugo CheinquerEdison Roberto PariseAlex FrançaMário Reis Alvares-DA-SilvaFlair Jose CarrilhoGabriela Perdomo CoralPaulo de Tarso Aparecida PintoLeila Maria Moreira Beltrão PereiraRaymundo ParanáRogério Camargo Pinheiro AlvesCarlos Eduardo Brandão-MelloPublished in: Arquivos de gastroenterologia (2023)
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide. The Brazilian Society of Hepatology (SBH) published in 2020 the updated recommendations for the diagnosis and treatment of HCC. Since then, new data have emerged in the literature, including new drugs approved for the systemic treatment of HCC that were not available at the time. The SBH board conducted an online single-topic meeting to discuss and review the recommendations on the systemic treatment of HCC. The invited experts were asked to conduct a systematic review of the literature on each topic related to systemic treatment and to present the summary data and recommendations during the meeting. All panelists gathered together for discussion of the topics and elaboration of the updated recommendations. The present document is the final version of the reviewed manuscript containing the recommendations of SBH and its aim is to assist healthcare professionals, policy-makers, and planners in Brazil and Latin America with systemic treatment decision-making of patients with HCC.